Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.30 |
| ▸ | BAD | Q92934 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607306 | 0.84 | ALDH1A1 (0.35) | ARNFE2L2NPC1RAB9AACHE | |
| SCHEMBL435279 | 0.83 | CYP1A2 (0.38) | MAOBARNFE2L2NPC1RAB9A | |
| SCHEMBL1491042 | 0.83 | ALDH1A1 (0.38) | NPC1RAB9A | |
| SCHEMBL5014600 | 0.81 | PTGS2 (0.39) | MAOBNPC1RAB9A | |
| SCHEMBL9650164 | 0.79 | NPC1 (0.35) | MAOBARNPC1RAB9ABCL2L1 | |
| SCHEMBL2012242 | 0.79 | MAPK1 (0.38) | NPC1RAB9A | |
| SCHEMBL11288386 | 0.79 | LMNA (0.39) | ARNPC1RAB9A | |
| SCHEMBL9646646 | 0.79 | GRM2 (0.31) | — | |
| SCHEMBL2011907 | 0.79 | KDM4E (0.38) | NPC1RAB9AACHE | |
| SCHEMBL6131965 | 0.79 | CYP3A4 (0.35) | MAOBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116544-A2 | Spirocyclic cyclohexane derivatives | Grünenthal GmbH (DE) | 2009-11-11 | — | — | EP | claimed |
| EP-0184308-B1 | PROCESS FOR PREPARING MILBEMYCIN DERIVATIVES AND CERTAIN NOVEL COMPOUNDS EMPLOYED THEREIN | SANKYO COMPANY LIMITED (JP) | 1989-12-27 | — | — | EP | claimed |
| EP-0031080-A1 | 2-Acylaminomethyl-1,4-benzodiazepines and their salts, as well as a process for their preparation and pharmaceutical compositions containing these compounds | Kali-Chemie Pharma GmbH (DE) | 1981-07-01 | — | — | EP | claimed |
| CN-105593217-A | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL CO | 2016-05-18 | — | — | CN | disclosed |
| CN-102569893-B | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | MITSUBISHI CHEMICAL CORP. (JP) | 2016-05-11 | — | — | CN | disclosed |
| EP-2430007-B1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | WISTA LAB LTD (SG) | 2014-02-12 | — | — | EP | disclosed |
| EP-2430007-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | Wista Laboratories Ltd. (SG) | 2012-03-21 | — | — | EP | disclosed |
| US-20120058995-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | WISTA LABORATORIES LTD. (SG) | 2012-03-08 | — | — | US | disclosed |
| EP-2391213-A1 | ACTIVE COMPOUND COMBINATIONS | Bayer CropScience AG (DE) | 2011-12-07 | — | — | EP | disclosed |
| EP-2391214-A1 | ACTIVE COMPOUND COMBINATIONS | Bayer CropScience AG (DE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010130977-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | WISTA LABORATORIES LTD. (SG) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010086120-A1 | ACTIVE COMPOUND COMBINATIONS | BAYER CROPSCIENCE AG (DE) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086109-A1 | ACTIVE COMPOUND COMBINATIONS | BAYER CROPSCIENCE AG (DE) | 2010-08-05 | — | — | WO | disclosed |
| WO-2002028829-A2 | PEPTIDE DEFORMYLASE INHIBITORS | QUESTCOR PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058995-A1 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INVOLVING THE USE OF PERSULFATE OXIDANTS | TST, TPMT, MGMT | MAOB 52/4885AR 2051/4885NFE2L2 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.